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High-Density Lipoprotein and
Residual Cardiovascular Risk
De Minimis Non Curat Medicus or the
COURAGE to be SMART?*
Jacques Genest, MD
Montreal, Quebec, Canada
Legal scholars and overburdened judges apply the rule of “De
minimis non curat praetor” (i.e., the praetor does not concern
himself with triﬂes), which loosely translates as: “don’t sweat
the small stuff.” Should physicians apply this rule to the
smallest (and, to many of us, the most noble) of lipopro-
teins? The study by van de Woestijne et al. (1) in this issue
of the Journal suggests that the measurement of high-density
lipoprotein cholesterol (HDL-C) in patients with estab-
lished atherosclerotic cardiovascular disease treated with
intensive low-density lipoprotein cholesterol (LDL-C)
lowering no longer predicts future cardiovascular events.
See pages 1826 and 1834
Patients were enrolled in the SMART (Second Manifesta-
tion of ARTerial disease) cohort, a prospective, ongoing
cohort study at the University Medical Center Utrecht in the
Netherlands. In patients receiving “intensive LDL-C
lowering” (a minimum of simvastatin 40 mg, atorvastatin
20 mg, rosuvastatin 5 mg; a combination of simvastatin 10
mg and ezetimibe 10 mg; or higher doses of statins),
decreasing quartiles of HDL-C did not predict adverse
cardiovascular outcomes.
A similar observation was made in the JUPITER (Justi-
ﬁcation for the Use of Statins in Primary Prevention: An
Intervention Trial Evaluating Rosuvastatin) trial (2). In
JUPITER, LDL-C was reduced by approximately 50% with
rosuvastatin 20 mg/day. HDL-C no longer predicted
recurrent events, while in patients on placebo, decreasing
quartiles of HDL-C were associated with increased cardio-
vascular risk. In the TNT (Treating to New Targets) trial
(3), patients treated with atorvastatin 80 mg had better*Editorials published in the Journal of the American College of Cardiology reﬂect the
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from the Heart and Stroke Foundation of Canada.outcomes than those treated with 10 mg. While overall,
high-density lipoprotein (HDL) predicted outcomes in the
TNT trial, this effect was markedly attenuated in patients
randomized to atorvastatin 80 mg/day (3). Similarly, the
PROVE-IT TIMI 22 trial (4) found no predictive value for
HDL-C in patients on atorvastatin 80 mg/day.
A different conclusion was reached by Acharjee et al. (5),
in this issue of the Journal, in a post-hoc analysis of the
COURAGE (Clinical Outcomes Utilizing revascularization
and Aggressive Drug Evaluation) trial. In the COURAGE
trial, HDL-C levels proved to be a strong determinant of
cardiovascular risk, even when stratiﬁed by LDL-C levels.
The COURAGE trial was a game-changer. Will its
conclusion re-focus our attention on the concept of
“residual” risk and prompt us to consider raising HDL-C
pharmacologically? The analysis of the COURAGE trial
data carefully attempted to remove sources of bias, and the
data robustly supports the authors’ conclusion that HDL-C
predicted outcomes. One could argue that patients in the
lowest HDL-C quartile in the COURAGE trial had
a higher burden of cardiovascular disease (myocardial
infarction, prior coronary artery bypass graft or percutaneous
coronary intervention, peripheral vascular disease, hyper-
tension, and diabetes) (5), but cardiovascular risk appears
continuous across the HDL-C range.
How, then, to explain discordant results in 2 carefully led
studies? The medications used or intensity of treatment does
not seem to provide an explanation. It is noteworthy
that only 29% of patients (634 of 2,186) in the COURAGE
trial achieved an LDL-C <70 mg/dl, a much smaller
percentage than in the PROVE-IT, TNT, and JUPITER
trials (the median LDL-C for patients on rosuvastatin
was 58 mg/dl (1.5 mmol/l) [2]). These differences are likely
due to the use of simvastatin, a weaker statin than atorvas-
tatin or rosuvastatin. Thus, when the LDL-C remains above
a certain level, yes, HDL-C will continue to predict risk.
The “HDL hypothesis” states that raising HDL-C
prevents cardiovascular disease, but this has been severely
challenged of late. The epidemiological association between
HDL-C and reduced cardiovascular risk is strong, graded,
coherent, and has withstood the test of multivariate
correction (6). Yet, Mendelian randomization has cast doubt
on whether some forms of genetically-determined low
HDL-C are associated with cardiovascular disease. Speciﬁ-
cally, mutations or single nucleotide polymorphisms at the
adenosine triphosphate binding cassette A1 (ABCA1) (7)
and lecithin:cholesterol acyl transferase (LCAT) (8) genes
that lower HDL-C are not associated with increased
cardiovascular risk. Conversely, single nucleotide poly-
morphisms at the cholesteryl ester transfer (CETP) and
endothelial lipase (EL-LIPG) genes that raise HDL-C do
not confer cardiovascular protection (9). Then, clinical trials
aimed at raising HDL-C with ﬁbrates in statin-treated
diabetic patients failed to show beneﬁt (10), even though
ﬁbrates may have a small beneﬁcial effect on nonfatal
cardiovascular events in studies performed without statins
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1843(11). Recently, dalcetrapib, a weak CETP inhibitor that
raised HDL-C by 31% to 40%, failed to prevent recurrent
cardiovascular events in patients with a recent acute coronary
syndrome when compared with placebo (12). Importantly,
dalcetrapib had no signiﬁcant effect on LDL-C. Niacin, or
vitamin B3, has long been used to treat lipoprotein disor-
ders, with encouraging results from small studies using
surrogate endpoints. The AIM-HIGH (Atherothrombosis
Intervention in Metabolic syndrome with low HDL/high
triglycerides: Impact on Global Health outcomes) trial (13)
failed to reduce cardiovascular risk in subjects with
established coronary artery disease and the metabolic
syndromedthe very patients in whom the drug is recom-
mended. While the AIM-HIGH trial was criticized for the
relatively small number of patients (n ¼ 3,300), the HPS-2
THRIVE (Heart Protection Study-2 Treatment of HDL to
Reduce the Incidence of Vascular Events) study of over
25,000 subjects at high cardiovascular risk on an aggressive
LDL-C lowering strategy failed to show any beneﬁt in
patients treated with the combination niacin/laropiprant
when compared with placebo (14). Thus, we are in a state of
clinical equipoise with clinical trials of HDL-raising thera-
pies, in which ﬁbrates, niacin, and dalcetrapib do not reduce
cardiovascular risk when the LDL-C is lowered to an
average of 70 mg/dl (1.8 mmol/l).
Yet, the biological plausibility for HDL as a target
remains strong. We probably have the wrong biomarker.
The HDL-C mass reﬂects a static measurement of a very
dynamic and diverse metabolic process and may not reﬂect
the function of HDL. HDL particles have multiple bio-
logical functions, including anti-inﬂammatory, antioxidant,
and antiapoptotic properties, as well as the release of nitric
oxide from vascular endothelial cells and differentiation of
vascular endothelial progenitor cells. These effects are
observed in vitro and in vivo animal models; their clinical
relevance remains unknown. The major effect of HDL, and
for which we have the most data, is the reverse cholesterol
transport, the mechanism by which cholesterol from
macrophages within an atherosclerotic plaque is brought
back to the liver for excretion as bile acids. The HDL
cholesterol efﬂux capacity is a novel biomarker of HDL
function that provides additional information on residual
cardiovascular risk, over and above the measurement of
HDL-C or the major apolipoprotein of HDL, apoA-I (15).
In very elegant sets of experiments, Besler et al. (16,17) have
explored the mechanisms of HDL function in vascular
endothelial cells and progenitor cells. These effects depend,
in part, on the lipid component of HDL, especially sphin-
golipids, not on cholesterol. The measurement of
sphignosine-1 phosphate, a sphingolipid involved in HDL-
mediated vascular endothelial cell signaling, may be another
determinant of HDL function (18). However, the biological
complexity of the human plasma lipidome is just starting to
be amenable to systematic analysis; there are over 200
sphingolipid species and 160 glycerophospholipids identiﬁed
in human lipoproteins (19). Furthermore, the proteincomposition of HDL, once thought to be relatively simple,
has shown remarkable biological diversity (20); there are
nearly 80 proteins identiﬁed in the HDL fraction, and the
HDL proteome is altered in inﬂammatory states, such as
acute coronary syndromes (21). Thus, it behooves us to
develop better markers of HDL function and to determine
whether these provide better prognostic information than
the HDL-C mass.
What should clinicians retain from these 2 papers? First,
current guidelines for the prevention and treatment of
cardiovascular disease should continue to focus on LDL-C
as the major therapeutic target. Non–HDL-C (i.e., the
sum of apo B-containing lipoproteins) or apo B itself are
solid therapeutic targets as well (22). Second, there is little
support from clinical trials to attempt to raise HDL-C
pharmacologically. To date, the trial evidence is at best
neutral; at worst, there is evidence of harm. Third, we might
have to rethink the link of causality between HDL-C and
cardiovascular disease. The Mendelian randomization data
casts doubt upon this association. Fourth, we need to
develop better biomarkers of HDL function and test them in
clinical trials.
There are many potential targets to improve HDL (23).
These must be rigorously tested in well-designed clinical
trials. For the time being, the concept of HDL-C as rep-
resenting an important proportion of residual cardiovascular
risk in patients on appropriate statin dosage is not well
supported by data. For the time being, at least, de HDL-C
non curat medicus. Stated differently, have the COURAGE
to be SMART: focus on LDL-C and non–HDL-C.
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